Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protara Therapeutics (TARA) Total Liabilities (2016 - 2026)

Protara Therapeutics' Total Liabilities history spans 14 years, with the latest figure at $10.7 million for Q1 2026.

  • Quarterly Total Liabilities rose 6.35% to $10.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $10.7 million through Mar 2026, up 6.35% year-over-year, with the annual reading at $13.1 million for FY2025, 8.83% down from the prior year.
  • Total Liabilities came in at $10.7 million for Q1 2026, down from $13.1 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $14.3 million in Q4 2024 to a low of $9.0 million in Q1 2022.
  • The 5-year median for Total Liabilities is $10.7 million (2026), against an average of $11.0 million.
  • Year-over-year, Total Liabilities surged 110.43% in 2022 and then fell 16.4% in 2024.
  • Protara Therapeutics' Total Liabilities stood at $11.2 million in 2022, then fell by 5.12% to $10.6 million in 2023, then skyrocketed by 34.68% to $14.3 million in 2024, then dropped by 8.83% to $13.1 million in 2025, then decreased by 17.93% to $10.7 million in 2026.
  • Per Business Quant, the three most recent readings for TARA's Total Liabilities are $10.7 million (Q1 2026), $13.1 million (Q4 2025), and $12.3 million (Q3 2025).